Syngene International Jumps 23%, FMCG falls reports As On 11 Aug, 2015

Nifty option tips

The Sensex down 19.91 points to 28081.81, and the Nifty also fell 10.35 points to 8515.25. Nearly 1062 shares have ahead, 1240 shares down, and 124 shares remains unchanged on BSE. Click Nifty option tips

 
Sun Pharmaceutical Industries, June quarter revenue are expected to be low-spirited on account of Ranbaxy concatenation. Country's largest drug company already given a warning, about its full year earnings performance, saying FY16 revenue will remains uniform or record marginal decline compared to FY15.

In addition to the above revenue impact, profits may also be adversely impacted due to certain expenses/charges arising out of integration as well as remedial actions, Sun said on July 20. However, Taro Pharma earnings, which displayed on August 6, may support a bit to overall earnings, analysts felt. The company will announce its Q1 earnings on 11th of August. Year-on-year numbers will not be comparable due to Ranbaxy integration. According to average of estimates of analysts, net profit is seen rising 0.6 percent sequentially to Rs 894 crore and revenue may increase 1.7 percent to Rs 6,262 crore in the quarter ended June. The muted growth may be on account of continued disruption in US sales from Halol facility, which added around 10% to total revenue.